CTAD 2025 | Integrating advancements in blood biomarkers for neurodegenerative diseases into primary care

Sid O’Bryant, PhD, Institute for Translational Research at UNT Health, Fort Worth, TX, comments on the significant advancements in blood biomarkers for neurodegenerative diseases and highlights the need to integrate these advancements into primary care. Dr O’Bryant emphasizes the importance of educating primary care physicians, nurses, and other healthcare professionals, as well as the community, to facilitate the implementation of these biomarkers and new treatments. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.